Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models ...

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, ...

The American Veterinary Medical Association (AVMA) has published an updated report on cannabis and pets, focusing on the ...

SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% ...

Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a ...

Detailed price information for Anebulo Pharmaceuticals Inc (ANEB-Q) from The Globe and Mail including charting and trades.

Early studies suggest that cannabis may ease chronic pelvic pain, but randomized trials are needed to confirm its benefits ...

As cannabis medicine becomes more advanced, so does our understanding of how cannabinoids interact with the body’s ...

Lean Body Mass: Improvements in lean body mass were aligned with total weight gains, suggesting preservation or accrual of muscle, consistent with pre-clinical research with ART27.13. Activity: ...

Inmed Pharmaceuticals Inc. ( ($INM) ) has released its Q4 earnings. Here is a breakdown of the information Inmed Pharmaceuticals Inc. presented to ...

Operating expenses in the fourth quarter of fiscal 2025 were $2.3 million compared with $1.3 million in the same period in fiscal 2024. Net loss in the fourth quarter of fiscal 2025 was $2.1 million, ...

InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline ...